Repligen (NASDAQ:RGEN) CFO Sells $106,285.00 in Stock

Repligen Corporation (NASDAQ:RGEN) CFO Jason Garland sold 733 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Repligen Price Performance

Shares of Repligen stock opened at $147.01 on Monday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The company’s 50 day moving average is $122.84 and its 200 day moving average is $135.36. The company has a market cap of $8.29 billion, a price-to-earnings ratio of 163.35, a price-to-earnings-growth ratio of 2.83 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $194.25 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Research analysts anticipate that Repligen Corporation will post 1.99 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen in the 3rd quarter worth approximately $29,000. Bayforest Capital Ltd acquired a new stake in shares of Repligen in the 4th quarter worth $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen during the 4th quarter worth $33,000. Los Angeles Capital Management LLC purchased a new position in Repligen during the 4th quarter worth $36,000. Finally, Farther Finance Advisors LLC increased its position in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on RGEN shares. JPMorgan Chase & Co. cut their price target on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Roth Mkm assumed coverage on Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective on the stock. HC Wainwright boosted their price objective on Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Finally, HSBC decreased their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $164.64.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.